BioCatalyst

cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab — catalyst calendar

1 verified catalyst event(s) referencing cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-11-02
in 4mo
ESTIMATED
 READOUT
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-
Phase 2 · Melanoma
 REGN REGENERON PHARMACEUTICALS, I cemiplimab, Fixed Dose Combination (FDC) ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.